aTyr Pharma/$ATYR
1D1W1MYTD1Y5YMAX
About aTyr Pharma
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
- Ticker
- $ATYR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 59
- Headquarters
- San Diego, United States
- Website
- atyrpharma.com
aTyr Pharma Metrics
BasicAdvanced
$56M
-
-$0.62
0.52
-
Price and volume
Market cap
$56M
Beta
0.52
52-week high
$6.50
52-week low
$0.40
Average daily volume
913K
Financial strength
Current ratio
5.121
Quick ratio
5.076
Long term debt to equity
20.239
Total debt to equity
23.252
Profitability
EBITDA (TTM)
-63.197
Gross margin (TTM)
-31,551.05%
Net profit margin (TTM)
-32,003.68%
Operating margin (TTM)
-33,609.47%
Management effectiveness
Return on assets (TTM)
-46.58%
Return on equity (TTM)
-98.68%
Valuation
Price to revenue (TTM)
293.663
Price to book
1.15
Price to tangible book (TTM)
1.15
Price to free cash flow (TTM)
-1.018
Free cash flow yield (TTM)
-98.28%
Free cash flow per share (TTM)
-0.56
Growth
Earnings per share change (TTM)
-21.84%
3-year revenue growth (CAGR)
-73.65%
3-year earnings per share growth (CAGR)
-18.86%
10-year earnings per share growth (CAGR)
-33.18%
What the Analysts think about aTyr Pharma
Analyst ratings (Buy, Hold, Sell) for aTyr Pharma stock.
aTyr Pharma Financial Performance
Revenues and expenses
aTyr Pharma Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.